Imagine if we could grow healthy heart muscle cells in a lab that anyone could receive without their body rejecting them. Instead of a custom-made treatment for every single person, this project creates a 'universal' set of cells that act like a spare part for a damaged heart. They've even added a built-in 'off switch' to destroy the cells if something goes wrong, making it much safer.
Heart failure treatments are limited and autologous stem cell therapies are too expensive and slow for mass adoption. There is a critical need for 'off-the-shelf' cell therapies that are safe, scalable, and compatible with many patients.
A GMP-compliant manufacturing process for HLA-homozygous cardiomyocyte aggregates, including a suicide-gene safety switch, AI-powered immune prediction algorithms, and validated cold-chain transport protocols.
If you are a cell therapy developer dealing with the high cost of patient-specific treatments — this project developed HLA-homozygous iPSC-CMAs that allow for allogeneic treatment. This enables a single product line to serve large patient populations with minimal immunosuppression.
If you are a device manufacturer dealing with invasive surgical requirements for cell delivery — this project developed and tested catheter-based delivery as a minimally invasive alternative. This expands the market for delivery tools used in heart repair.
If you are a CDMO dealing with scaling lab-grown cells to industrial volumes — this project developed scalable production from 20mL to 500mL cultures. It includes GMP-compliant SOPs and 24-hour cold transport protocols to ensure product stability.
The provided data does not specify the final price per dose, but it notes that allogeneic approaches are designed to overcome the economic barriers associated with autologous treatments.
Yes, the project achieved scalable iPSC expansion and cardiomyocyte production, increasing culture volumes from 20mL to 500mL.
The project specifically established freedom to operate and licensing strategies to prepare for the approval of the cell product and its distribution.
Safety is managed through a biallelic suicide gene for programmed cell death and a mutation categorization system to ensure genomic integrity.
The project period ends on 2027-02-28, with the goal of initiating a first-in-man (FIM) clinical trial.
The consortium is well-balanced for translation, consisting of 11 partners across 6 countries. With a 36% industry ratio (4 companies, including 3 SMEs), there is a strong bridge between the 6 universities and the commercial market, ensuring that the GMP bioprocessing and licensing strategies are grounded in industrial reality.
Contact the Medizinische Hochschule Hannover for licensing and FIM trial collaboration.
Contact SciTransfer to connect with the HEAL consortium for licensing the HLA-homozygous cell lines.
